Hypolipidemic Effect of Mannan in Mice with Acute Lipemia Induced by Poloxamer 407
- Authors: Goncharova N.V.1, Khrapova M.V.1, Pupyshev A.B.1, Korolenko E.T.2, Nešéáková Z.3, Korolenko T.A.1
-
Affiliations:
- Research Institute of Physiology and Fundamental Medicine
- University Canada West
- Institute of Chemistry, Slovak Academy of Sciences
- Issue: Vol 162, No 1 (2016)
- Pages: 18-22
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/237866
- DOI: https://doi.org/10.1007/s10517-016-3534-8
- ID: 237866
Cite item
Abstract
We studied biological effects of mannan, a polysaccharide immunomodulator from C. albicans, that interacts with mannose receptor in vivo. It is shown that preliminary administration of mannan (5 times in a dose of 50 mg/kg or 2 times in a dose of 100 mg/kg) to mice with acute lipemia induced by lipase inhibitor poloxamer 407 (300 mg/kg) reduces the serum concentrations of atherogenic LDL, cholesterol, and triglycerides. Administration of mannan to intact mice and animals with acute lipemia reduces triglyceride concentration and causes labilization of lysosomal membranes in the liver. Serum activity of chitotriosidase, a marker of macrophage activation, was elevated in mice with acute lipemia treated with mannan. Thus, mannan from C. albicans is a promising hypolipidemic polysaccharide compound, similar by its activity to β-glycan, a component of LPS.
About the authors
N. V. Goncharova
Research Institute of Physiology and Fundamental Medicine
Email: t.a.korolenko@physiol.ru
Russian Federation, Novosibirsk
M. V. Khrapova
Research Institute of Physiology and Fundamental Medicine
Email: t.a.korolenko@physiol.ru
Russian Federation, Novosibirsk
A. B. Pupyshev
Research Institute of Physiology and Fundamental Medicine
Email: t.a.korolenko@physiol.ru
Russian Federation, Novosibirsk
E. Ts. Korolenko
University Canada West
Email: t.a.korolenko@physiol.ru
Canada, Vancouver
Z. Nešéáková
Institute of Chemistry, Slovak Academy of Sciences
Email: t.a.korolenko@physiol.ru
Slovakia, Bratislava
T. A. Korolenko
Research Institute of Physiology and Fundamental Medicine
Author for correspondence.
Email: t.a.korolenko@physiol.ru
Russian Federation, Novosibirsk